Humana Inc to Post Q2 2019 Earnings of $4.78 Per Share, Piper Jaffray Companies Forecasts (HUM)

Humana Inc (NYSE:HUM) – Stock analysts at Piper Jaffray Companies dropped their Q2 2019 earnings per share estimates for shares of Humana in a research report issued to clients and investors on Wednesday, November 7th. Piper Jaffray Companies analyst S. James now anticipates that the insurance provider will earn $4.78 per share for the quarter, down from their prior estimate of $4.96. Piper Jaffray Companies currently has a “Overweight” rating and a $380.00 target price on the stock. Piper Jaffray Companies also issued estimates for Humana’s Q4 2019 earnings at $3.30 EPS, FY2019 earnings at $17.20 EPS, Q2 2020 earnings at $5.62 EPS and FY2020 earnings at $19.60 EPS.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, November 7th. The insurance provider reported $4.58 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $4.29 by $0.29. The company had revenue of $14.21 billion during the quarter, compared to analyst estimates of $13.97 billion. Humana had a return on equity of 17.43% and a net margin of 2.48%. During the same period in the prior year, the company earned $3.39 earnings per share.

Several other equities analysts also recently issued reports on HUM. Credit Suisse Group boosted their price objective on Humana from $370.00 to $390.00 and gave the stock an “outperform” rating in a research report on Thursday. MED reiterated an “outperform” rating and set a $373.00 price objective (up from $350.00) on shares of Humana in a research report on Thursday. SunTrust Banks reiterated a “hold” rating and set a $350.00 price objective on shares of Humana in a research report on Thursday, August 2nd. Cowen began coverage on Humana in a research report on Monday, September 17th. They set a “market perform” rating and a $372.00 price objective for the company. Finally, Royal Bank of Canada reiterated a “hold” rating and set a $318.00 price objective on shares of Humana in a research report on Thursday, August 2nd. Seven research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Humana presently has an average rating of “Buy” and an average target price of $352.30.

Shares of NYSE HUM traded down $0.07 during midday trading on Friday, hitting $339.52. 2,565 shares of the company’s stock were exchanged, compared to its average volume of 605,449. The company has a current ratio of 1.43, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. The company has a market cap of $45.71 billion, a PE ratio of 28.95, a P/E/G ratio of 1.65 and a beta of 1.03. Humana has a twelve month low of $231.90 and a twelve month high of $355.88.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. PNC Financial Services Group Inc. increased its stake in shares of Humana by 9.7% in the third quarter. PNC Financial Services Group Inc. now owns 41,018 shares of the insurance provider’s stock worth $13,885,000 after acquiring an additional 3,634 shares during the last quarter. Girard Partners LTD. acquired a new position in shares of Humana in the third quarter worth $169,000. Artemis Investment Management LLP increased its stake in shares of Humana by 74.6% in the third quarter. Artemis Investment Management LLP now owns 262,042 shares of the insurance provider’s stock worth $88,676,000 after acquiring an additional 111,991 shares during the last quarter. Rational Advisors LLC increased its stake in shares of Humana by 4,713.5% in the third quarter. Rational Advisors LLC now owns 2,503 shares of the insurance provider’s stock worth $848,000 after acquiring an additional 2,451 shares during the last quarter. Finally, FormulaFolio Investments LLC acquired a new position in shares of Humana in the third quarter worth $239,000. 92.62% of the stock is currently owned by institutional investors and hedge funds.

In other news, insider Elizabeth D. Bierbower sold 3,092 shares of the company’s stock in a transaction on Thursday, August 16th. The shares were sold at an average price of $330.00, for a total value of $1,020,360.00. Following the transaction, the insider now directly owns 14,289 shares of the company’s stock, valued at $4,715,370. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Bruce D. Broussard sold 18,000 shares of the company’s stock in a transaction on Monday, September 10th. The stock was sold at an average price of $328.66, for a total transaction of $5,915,880.00. Following the completion of the transaction, the chief executive officer now directly owns 71,085 shares in the company, valued at $23,362,796.10. The disclosure for this sale can be found here. 0.60% of the stock is owned by insiders.

The company also recently announced a quarterly dividend, which will be paid on Friday, January 25th. Shareholders of record on Monday, December 31st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 0.59%. The ex-dividend date of this dividend is Friday, December 28th. Humana’s dividend payout ratio (DPR) is currently 17.08%.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

See Also: No Load Funds

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply